Pregabalin is used to treat nerve pain from diabetes or shingles, and it also helps reduce seizures and anxiety. It works by calming overactive nerves in the body that cause pain and other symptoms.[2] Lyrica is currently approved and in use across 74 indications[4].[1]
Lyrica is one of 853 small molecule programs targeting Pruritus. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
706 competitors in Breast Cancer
Lyrica
Adenocard
Lexiscan
Voltaren
Zolymbus
Blenoxane
Methylthioninium Chloride
MS Contin
Duragesic-100
MS Contin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Dec 30, 2004
LYRICA
NDA NDA021446
Dec 30, 2004
LYRICA
NDA NDA021446
Feb 17, 2006
LYRICA
NDA NDA021446
Feb 17, 2006
LYRICA
NDA NDA021446
Oct 27, 2006
LYRICA
NDA NDA021446
Jun 21, 2007
LYRICA
NDA NDA021446
Apr 23, 2009
LYRICA
NDA NDA021446
Apr 23, 2009
LYRICA
NDA NDA021446
Jan 4, 2010
LYRICA
NDA NDA021446
Jan 4, 2010
LYRICA
NDA NDA022488
Oct 8, 2010
LYRICA
NDA NDA021446
Apr 26, 2011
LYRICA
NDA NDA021446
Apr 26, 2011
LYRICA
NDA NDA021446
Apr 26, 2011
LYRICA
NDA NDA022488
Apr 26, 2011
LYRICA
NDA NDA022488
Apr 26, 2011
LYRICA
NDA NDA022488
Jun 20, 2011
LYRICA
NDA NDA022488
Jun 20, 2011
LYRICA
NDA NDA021446
Aug 24, 2011
LYRICA
NDA NDA022488
Aug 24, 2011
LYRICA
NDA NDA021446
Apr 16, 2012
LYRICA
NDA NDA022488
Jun 20, 2012
LYRICA
NDA NDA021446
Feb 28, 2013
LYRICA
NDA NDA022488
Dec 23, 2013
LYRICA
NDA NDA022488
Dec 23, 2013
LYRICA
NDA NDA021446
Mar 9, 2016
LYRICA
NDA NDA022488
Mar 9, 2016
LYRICA
NDA NDA021446
Jul 8, 2016
LYRICA
NDA NDA021446
Dec 22, 2016
LYRICA
NDA NDA021446
Dec 22, 2016
LYRICA
NDA NDA022488
Oct 11, 2017
LYRICA CR
NDA NDA209501
Oct 11, 2017
LYRICA CR
NDA NDA209501
May 3, 2018
LYRICA
NDA NDA022488
May 3, 2018
LYRICA
NDA NDA021446
May 23, 2019
LYRICA
NDA NDA022488
May 23, 2019
LYRICA
NDA NDA021446
Apr 3, 2020
LYRICA
NDA NDA022488
Apr 3, 2020
LYRICA
NDA NDA021446
Apr 3, 2020
LYRICA CR
NDA NDA209501
Dec 13, 2023
LYRICA
NDA NDA021446
Dec 13, 2023
LYRICA CR
NDA NDA209501
Dec 13, 2023
LYRICA
NDA NDA022488
Apr 25, 2025
LYRICA
NDA NDA022488
Apr 25, 2025
LYRICA
NDA NDA021446
Apr 25, 2025
LYRICA CR
NDA NDA209501
Sources
Details
Patent Cliff
May 2, 2027
Earliest patent expiration — generic entry possible after this date